Home › Ovarian Cancer › NCT04997096
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study Exclusion Criteria: * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
About the study
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
What is being tested
- Exercise (other)
- Attention Control (other)
Sponsor: Dana-Farber Cancer Institute · Participants: 30 · Started: Apr 2, 2022
Contact the study team
- Christina Dieli-Conwright, PhD · Phone: (617) 582-8321
Official record on ClinicalTrials.gov — NCT04997096
Locations in the U.S.
| Massachusetts | Dana Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.